Effect of BDNF Val66Met on memory decline and hippocampal atrophy in prodromal alzheimer's disease: A preliminary study

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Lim, Yen Ying ^a   Villemagne, Victor L ^a,b   Laws, Simon M ^c,d,e   Ames, David ^a,f   Pietrzak, Robert H ^g   Ellis, Kathryn A ^a,f   Harrington, Karra ^a   Bourgeat, Pierrick ^h   Bush, Ashley I ^a   Martins, Ralph N ^c,d   Masters, Colin L ^a   Rowe, Christopher C ^a,b   Maruff, Paul ^a,i  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^e Sir James McCusker Alzheimer's Disease Research Unit Hollywood Private Hospital ^*  (Australia)

^f NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CSIRO   (Australia)

ⁱ Department of Psychiatry Yale University School of Medicine ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUSTRALIA; BDNF GENE; BRAIN ATROPHY; BRAIN RADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EPISODIC MEMORY; FEMALE; GENOTYPE; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; MALE; MEMORY; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; AUSTRALIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEMORY DISORDERS; MILD COGNITIVE IMPAIRMENT; MUTATION, MISSENSE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84899941795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086498     Document Type: Article

References (27)

1. Masters CL, Selkoe DJ (2012) Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer Disease. In: Selkoe DJ, Mandelkow E, Holtzman DM, editors. The Biology of Alzheimer Disease. New York: Cold Spring Harbor Laboratory Press. pp. 1812204.
2. Hariri AR, Goldberg TE, Mattay VS, Kolachana BS, Callicott JH, et al. (2003) Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. The Journal of Neuroscience 23: 669026694.
3. Fahnestock M (2011) Brain-derived neurotrophic factor: The link between amyloid-b and memory loss. Future Neurology 6: 6272639.
4. Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nature Reviews, Neuroscience 14: 4012416.
5. Garzon DJ, Fahnestock M (2007) Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. The Journal of Neuroscience 27: 262822635.
6. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the preclinical stages of Alzheimer's disease. Journal of Neurochemistry 93: 141221421.
7. Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, et al. (2011) The brain-derived neurotrophic factor val66met polymorphism and prediction of neural risk for Alzheimer disease. Archives of General Psychiatry 68: 1982206.
8. Lim YY, Villemagne VL, Laws SM, Ames D, Pietrzak RH, et al. (2013) BDNF Val66Met, Aβ amyloid and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging 34: 245722464.
9. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, et al. (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging 31: 127521283.
10. Villemagne VL, Pike KE, Chételat G, Ellis KA, Mulligan RS, et al. (2011) Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology 69: 1812192.
11. Chételat G, Villemagne VL, Villain N, Jones G, Ellis KA, et al. (2012) Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition. Neurology 78: 4772484.
12. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, et al. (in press) Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain.
13. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al. (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimer's & Dementia 7: 2702279.
14. Lim YY, Ellis KA, Harrington K, Pietrzak RH, Gale J, et al. (2013) Cognitive decline in adults with mild cognitive impairment and high Aβ amyloid: Prodromal Alzheimer's disease? Journal of Alzheimer's Disease 33: 116721176.
15. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, et al. (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics 21: 6722687.
16. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, et al. (1999) Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 56: 3032308.
17. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, et al. (2004) Mild cognitive impairment - beyond controversies, towards a consensus: Report of the International Working Group on mild cognitive impairment. Journal of Internal Medicine 256: 2402246.
18. Collins DL, Zijdenbos AP, Kollokian V, Sled JG, Kabani NJ, et al. (1998) Design and construction of a realistic digital brain phantom. IEEE Trans Med Imaging 17: 4632468.
19. Ourselin S, Roche A, Subsol G, Pennec X, Ayache N (2001) Reconstructing a 3D structure from serial histological sections. Image and Vision Computing: 25231.
20. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, et al. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 2572269.
21. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, et al. (2006) BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biological Psychiatry 59: 8122815.
22. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nature Genetics 39: 17223.
23. Ventriglia M, Bocchio Chiavetto L, Benussi L, Binetti G, Zanetti O, et al. (2002) Association between the BDNF 196 A/G polymorphism and sporadic Alzheimer's disease. Molecular Psychiatry 7: 1362137.
24. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, et al. (2009) Longitudinal modeling of age-related memory decline and the APOE ε4 effect. The New England Journal of Medicine 361: 2552263.
25. Reiman EM, Chen K, Liu XF, Bandy D, Yu MX, et al. (2009) Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 106: 682026825.
26. Lee ST, Chu K, Jung KH, Kim JH, Huh JY, et al. (2012) miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model. Annals of Neurology 72: 2692277.
27. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, et al. (2010) Effects of aerobic exercise on mild cognitive impairment: A controlled trial. Archives of Neurology 67: 71279.